Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00202982 · ClinicalTrials.gov registry record · Phase 2
A Study to Test the Effectiveness and Safety of a New Higher 40mg Dose of Copaxone® Compared to Copaxone® 20mg, the Currently Approved Dose
A Phase 2 study, sponsored by Teva Branded Pharmaceutical Products R&D.
- Completed
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
NCT00202982 is a Phase 2 study that has completed, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 90 participants.
The verdict
NCT00202982, a Phase 2 study, has completed, sponsored by Teva Branded Pharmaceutical Products R&D.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
Study Summary
This is a study to test if a new higher dose of Copaxone is more effective in treating relapsing-remitting multiple sclerosis than the currently available 20 mg dose.
Interventions
- DRUG glatiramer acetate 20 mg
- DRUG glatiramer acetate 40 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2003-08 |
| Est. Completion | 2005-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00202982
The ClinicalTrials.gov registry entry for NCT00202982 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Branded Pharmaceutical Products R&D, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which glatiramer acetate 20 mg is the first listed.
NCT00202982 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00202982 about?
NCT00202982 is a clinical study titled "A Study to Test the Effectiveness and Safety of a New Higher 40mg Dose of Copaxone® Compared to Copaxone® 20mg, the Currently Approved Dose". This is a study to test if a new higher dose of Copaxone is more effective in treating relapsing-remitting multiple sclerosis than the currently available 20 mg dose.
What is the current status of trial NCT00202982?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2003-08. Estimated completion is 2005-09.
What interventions are being tested in trial NCT00202982?
The interventions under investigation include: glatiramer acetate 20 mg (DRUG), glatiramer acetate 40 mg (DRUG).
Who is sponsoring clinical trial NCT00202982?
This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.